<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00768287</url>
  </required_header>
  <id_info>
    <org_study_id>IB1001-01</org_study_id>
    <nct_id>NCT00768287</nct_id>
  </id_info>
  <brief_title>Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B</brief_title>
  <official_title>Phase I/II/III Pharmacokinetic and Outcome Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aptevo BioTherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aptevo Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety (acute effects associated with infusions, and inhibitor development),
      pharmacokinetics (PK), and efficacy with respect to breakthrough bleeding during prophylaxis
      and with respect to control of hemorrhaging in both the prophylaxis and on demand groups of
      IB1001 in subjects with hemophilia B.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2009</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>degree of hemorrhage control by treatment regimen</measure>
    <time_frame>throughout the study</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Hemophilia B</condition>
  <arm_group>
    <arm_group_label>IB1001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IB1001 (On-Demand)</intervention_name>
    <description>use as needed</description>
    <arm_group_label>IB1001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IB1001 (Prophylaxis)</intervention_name>
    <description>use on a prophylaxis basis</description>
    <arm_group_label>IB1001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient must be willing to give written Institutional Review Board (IRB)/Independent
             Ethics Committee (IEC)-approved informed consent, make the required study visits, and
             follow instructions while enrolled in the study

          2. Severe (factor IX activity ≤2 U/dL) hemophilia B subjects on demand therapy with a
             minimum of 3 bleeding episodes over the preceding 6 months or 6 bleeding episodes over
             the preceding 12 months; subjects on prophylaxis with a bleeding pattern as above
             demonstrated prior to starting prophylaxis

          3. Immunocompetent (CD4 count &gt;400/mm3) and not receiving immune modulating or
             chemotherapeutic agents

          4. Previously treated patients with a minimum of 150 exposure days to a factor IX
             preparation

          5. Platelet count at least 150,000/mm3

          6. Liver function: alanine transaminase [ALT] and aspartate transaminase [AST] ≤2 times
             the upper limit of the normal range

          7. Total bilirubin ≤1.5 times the upper limit of the normal range

          8. Renal function: serum creatinine ≤1.25 times the upper limit of the normal range

          9. Willingness to participate in the trial for up to 12-15 months

         10. European Union (EU), Israel, and Canada: Age of at least 12 years and body weight of
             ≥40 kilograms to participate in any PK Study or the Surgical Sub-study [the Surgical
             Sub-study does not apply to the UK]; age of at least 12 years for the prophylaxis and
             on demand components of the Treatment Phase and Continuation Study

             United States (US): Age of at least 12 years and body weight of ≥40 kilograms to
             participate in any PK Study or the Surgical Sub-study; age of at least 5 years for the
             prophylaxis and on demand components of the Treatment Phase and Continuation Study

         11. Hemoglobin ≥7 g/dL at the time of the blood draw

        Exclusion Criteria:

          1. History of factor IX inhibitor ≥0.6 Bethesda units (BU)

          2. Existence of another coagulation disorder

          3. Evidence of thrombotic disease, fibrinolysis, or disseminated intravascular
             coagulation (DIC)

          4. Use of an investigational drug within 30 days prior to study entry

          5. On medications that could impact hemostasis, such as aspirin

          6. History of poor compliance, a serious medical or social condition, or any other
             circumstance that, in the opinion of the investigator, would interfere with
             participation or compliance with the study protocol

          7. History of adverse reaction to either plasma-derived factor IX or recombinant factor
             IX that interfered with the subject's ability to treat bleeding episodes with a factor
             IX product
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hemophilia Treatment Center of Orthopaedic Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine Pediatric Hematology</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center-Pediatric Hematology Oncology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Hemophilia &amp; Thrombosis Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Center for Bleeding and Clotting Disorder</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hemophilia Treatment Center of Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hemophilia and Thrombosis Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center-Houston, Gulf States Hemophilia &amp; Thrombophilia Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Traitement de l 'Hemophilie</name>
      <address>
        <city>Nantes</city>
        <state>Loire-Atlantique</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahyadri Specialty Hospital, Deccan Gymkhana</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411 004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jehangir Clinical Development Centre</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411 011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The National Hemophilia Center-Sheba MC</name>
      <address>
        <city>Tel Hashomer</city>
        <state>Ramat Gan</state>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Careggi</name>
      <address>
        <city>Florence</city>
        <zip>I-50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Milan</name>
      <address>
        <city>Milano</city>
        <zip>I-20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MTZ Clinical Research</name>
      <address>
        <city>Warsaw</city>
        <zip>02-106</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Haemophilia Comprehensive Care Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S102JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Haemostasis and Thrombosis, Basingstoke and North Hampshire Foundation Trust</name>
      <address>
        <city>Basingstoke</city>
        <state>Hampshire</state>
        <zip>RG24 9NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales Health Park</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF4 4XN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2008</study_first_submitted>
  <study_first_submitted_qc>October 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2008</study_first_posted>
  <last_update_submitted>June 26, 2017</last_update_submitted>
  <last_update_submitted_qc>June 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>March 27, 2018</submitted>
    <returned>April 26, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

